RIBOLIFE-B(06938),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06938 RIBOLIFE-B

Trading 04-27 15:02:36

61.050

-1.450

-2.32%

High64.950	Low61.050	Vol110.60K
Open63.000	D1 Closing62.500	Amplitude6.24%
Mkt Cap10.41B	Tradable Cap10.41B	Total Shares170.55M
T/O6.88M	T/O Rate0.06%	Tradable Shares170.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":61.05,"timestamp":1777273303854,"preClose":62.5,"halted":0,"volume":110600,"delay":0,"changeRate":-0.023200000000000047,"floatShares":170554910,"shares":170554910,"eps":-2.100221,"marketStatus":"Trading","change":-1.45,"latestTime":"04-27 15:02:36","open":63,"high":64.95,"low":61.05,"amount":6881565,"amplitude":0.0624,"askPrice":61.3,"askSize":1200,"bidPrice":61.05,"bidSize":1400,"shortable":0,"etf":0,"ttmEps":-1.805,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777277400000},"marketStatusCode":2,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":62.5,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"volumeRatio":0.862448,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"1120235638","title":"RIBOLIFE-B聚焦创新药管线，2025年营收小幅增长但仍录净亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=1120235638","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120235638?lang=en_us&edition=fundamental","pubTime":"2026-04-17 17:10","pubTimestamp":1776417031,"startTime":"0","endTime":"0","summary":"苏州瑞博生物科技有限公司（RIBOLIFE-B，香港联交所股票代码：06938）公布截至2025年12月31日止年度业绩，并在报告期内于核酸药物研发管线上取得重要进展。公司实现全年收入约人民币1.485亿元（较2024年增长4.1%），但大规模研发投入及管理开支推动全年仍录得净亏损。 经营及财务表现...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628279222","title":"Suzhou Ribo Life Science publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2628279222","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628279222?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:40","pubTimestamp":1776415202,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science published 2025 annual report highlighting pipeline progress across cardiovascular, metabolic, renal, and liver programs.Phase 2 trial for core candidate vortosiran  was basically completed, reinforcing its positioning as an FXI-targeting siRNA with long duration of effect.China Phase 2 trial for RBD5044 began in February 2026 following January 2026 clearance, supporting broader development alongside ongoing European work.Partner-led PCSK9 program RBD7022  moved toward Phase 3 initiation in China, marking first in-house-originated asset set to enter Phase 3.Report flagged strategic expansion via a Madrigal collaboration valued at more than USD 4.4 billion, alongside progress in extra-hepatic delivery research targeting kidney, heart, and adipose tissue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL525421:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","06938","BK4590","BK1161","UAN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182190562","title":"RIBOLIFE-B Shares Surge Over 7% in Morning Session Following Successful Phase IIb Submission for Vortosiran in Stroke Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=1182190562","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182190562?lang=en_us&edition=fundamental","pubTime":"2026-04-15 11:33","pubTimestamp":1776224004,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) rose more than 7% during early trading. At the time of writing, the stock was up 6.04%, trading at HK$72.9, with a turnover of HK$11.7261 million. The company announced that its...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161","BK4588","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135129754","title":"RIBOLIFE-B (06938) Submits Application for Phase 2b Trial of Core Product VORTOSIRAN in SPAF Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1135129754","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135129754?lang=en_us&edition=fundamental","pubTime":"2026-04-14 08:08","pubTimestamp":1776125301,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that its core product, Vortosiran (RBD4059), has successfully submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase 2b trial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627252464","title":"Suzhou Ribo submits EMA phase 2b trial application for Vortosiran in SPAF","url":"https://stock-news.laohu8.com/highlight/detail?id=2627252464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627252464?lang=en_us&edition=fundamental","pubTime":"2026-04-14 08:00","pubTimestamp":1776124845,"startTime":"0","endTime":"0","summary":"Suzhou Ribo submitted Phase 2b clinical trial application to European Medicines Agency for Vortosiran in stroke prevention in atrial fibrillation.Vortosiran  targets factor XI via siRNA, aiming to reduce thromboembolic risk with lower bleeding risk than current anticoagulants.Company said Vortosiran Phase 2a trial in coronary artery disease in Europe has been completed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL6dkqmC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157500309","title":"RIBOLIFE-B Maintains Stable Share Capital in March; 2.11 Million Pre-IPO Options Remain Unexercised","url":"https://stock-news.laohu8.com/highlight/detail?id=1157500309","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157500309?lang=en_us&edition=fundamental","pubTime":"2026-04-09 17:05","pubTimestamp":1775725511,"startTime":"0","endTime":"0","summary":"For the month ended 31 March 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its authorised, registered or issued share capital. Authorised and issued ordinary H-shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172541363","title":"China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1172541363","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172541363?lang=en_us&edition=fundamental","pubTime":"2026-04-03 10:54","pubTimestamp":1775184869,"startTime":"0","endTime":"0","summary":"According to statistics from the NMPA and PharmaGO, the total business development value for domestic innovative drugs in the first quarter of 2026 exceeded $60 billion, surpassing the full-year 2024...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","159992","BK1588","LU0540923850.HKD","BK1515","LU1969619763.USD","01276","LU0359201612.USD","BK1191","LU1720050803.USD","06978","IE00B543WZ88.USD","LU0348735423.USD","LU0417516571.SGD","09926","LU0348827113.USD","IE00BPRC5H50.USD","LU0348767384.USD","LU2543165471.USD","LU0348783233.USD","LU0359202008.SGD","LU1961090484.USD","LU0348766576.USD","LU0561508036.HKD","LU0348825331.USD","09995","06938","LU1303224171.USD","LU0348784397.USD","LU0417516738.SGD","BK1500","LU2399975544.HKD","LU2476274720.SGD","LU1719994722.HKD","LU0634319403.HKD","LU0307460666.USD","LU0588546209.SGD","LU1023057109.AUD","BK1574","LU0359201885.HKD","LU2778985437.USD","BK1583","06160","IE00B5MMRT66.SGD","LU0417516902.SGD","LU1770034418.SGD","LU2488822045.USD","LU1251922891.USD","LU1794554557.SGD","LU2328871848.SGD","LU2476274308.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868063","title":"Shrinking Losses At Suzhou Ribo Life Science (SEHK:6938) Test Bearish Profitability Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868063","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868063?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:19","pubTimestamp":1774523958,"startTime":"0","endTime":"0","summary":"Setting the Scene: Suzhou Ribo Life Science's Latest Numbers\nSuzhou Ribo Life Science (SEHK:6938) has posted another loss for FY 2025, with first half revenue of ¥103.8 million and a basic EPS loss of ¥0.68, while trailing twelve month revenue sits at ¥148.5 million against a TTM EPS loss of ¥2.11. Looking back, revenue has moved from ¥66.3 million in 1H 2024 to ¥76.3 million in 2H 2024 and then to ¥103.8 million in 1H 2025, while basic EPS losses over these halves have gone from ¥1.07 to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/shrinking-losses-at-suzhou-ribo-life-science-sehk6938-test-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/shrinking-losses-at-suzhou-ribo-life-science-sehk6938-test-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199028891","title":"RIBOLIFE-B (06938) Proposes Adoption of H Share Option Scheme and H Share Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1199028891","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199028891?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:55","pubTimestamp":1774450531,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that on March 25, 2026, the board of directors resolved to propose the adoption of the company's H Share Option Scheme and H Share Incentive Plan (collectively referred...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130407819","title":"RIBOLIFE-B Reports 2025 Revenue of Approximately 1.485 Billion Yuan, Up 4.1% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1130407819","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130407819?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:43","pubTimestamp":1774449788,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced its 2025 financial results, achieving revenue of approximately 1.485 billion yuan, representing a 4.1% increase compared to the previous year. Gross profit reached about...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164454835","title":"RIBOLIFE-B Appoints Anders Gabrielsen as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=1164454835","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164454835?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:42","pubTimestamp":1774449767,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced the appointment of Dr. Anders Gabrielsen as Chief Medical Officer. Dr. Gabrielsen will oversee the company's overall clinical development, medical affairs, and regulatory...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147245685","title":"Ribo Life Science Names New Chief Medical and Business Officers, Effective 25 March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1147245685","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147245685?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:41","pubTimestamp":1774449667,"startTime":"0","endTime":"0","summary":"On 25 March 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced senior management changes aimed at strengthening its global clinical and commercial operations. Dr. Anders...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072652","title":"Suzhou Ribo Life Science Co Ltd -  FY Revenue RMB148.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072652","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072652?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:30","pubTimestamp":1774449009,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0XQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622725680","title":"Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622725680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622725680?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:29","pubTimestamp":1774448990,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science posted FY2025 loss before tax that widened 10.7% to RMB285 million.FY2025 administrative expenses jumped 28% to RMB118 million on higher listing expenses and increased professional and consulting service fees.FY2025 loss per share widened to RMB2.11 from RMB2.10.FY2025 revenue rose 4.1% to RMB149 million on higher collaboration revenue from the Boehringer Ingelheim agreement and higher sales of nucleoside monomers-related products.FY2025 gross profit climbed 3.3% to RMB135 million, while gross profit margin fell 0.8 percentage points to 90.9%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Infor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLFDTsT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620381687","title":"Suzhou Ribo Life Science Attends RNA Leaders Europe Conference in Vienna","url":"https://stock-news.laohu8.com/highlight/detail?id=2620381687","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620381687?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:33","pubTimestamp":1774006383,"startTime":"0","endTime":"0","summary":"Ribo attended the RNA Leaders Europe conference in Vienna, where it delivered a presentation.The company discussed its RiboPepSTAR platform for targeted delivery of siRNA therapies to organs outside the liver.Ribo said preclinical studies showed up to 80% target gene expression reduction in kidney proximal tubular cells.Ribo reported a 96% gene expression reduction in adipose tissue in non-human primates.Ribo said RiboGalSTAR has supported seven clinical programs and partnerships valued at more than USD 6 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via PR Newswire  on March 20, 2026, and is solely responsible for the informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL7X0SXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620144844","title":"Suzhou Ribo Life Science to present ex-hepatic siRNA delivery data at RNA Leaders Europe Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620144844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620144844?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:00","pubTimestamp":1773716414,"startTime":"0","endTime":"0","summary":"Ribo is scheduled to speak at the RNA Leaders Europe Conference in Vienna, Austria on March 19, 2026. Event materials are available at .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9GWGgm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166601011","title":"RIBOLIFE-B (06938) Sets 25 Mar 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1166601011","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166601011?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:02","pubTimestamp":1773309771,"startTime":"0","endTime":"0","summary":"According to the announcement released by Suzhou Ribo Life Science Co., Ltd. (stock code: 06938, “RIBOLIFE-B”), the Board of Directors will convene on Wednesday, 25 March 2026. The agenda includes:...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618180268","title":"Suzhou Ribo Life Science to hold board meeting to approve 2025 annual results and consider final dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2618180268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618180268?lang=en_us&edition=fundamental","pubTime":"2026-03-12 17:52","pubTimestamp":1773309136,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science will hold a board meeting on March 25, 2026 to consider and approve the group’s annual results for the year ended December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL5Y8m4k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197218581","title":"RIBOLIFE-B (06938) Announces Increase in Issued H Shares Following Over-Allotment Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1197218581","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197218581?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:51","pubTimestamp":1772704304,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (Stock Code: 06938, RIBOLIFE-B) disclosed monthly return information for the period ended February 28, 2026. The total issued H shares rose from 165.81 million to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176092556","title":"Citigroup Initiates Coverage on RIBOLIFE-B with Buy Rating, Sets HK$102 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1176092556","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176092556?lang=en_us&edition=fundamental","pubTime":"2026-03-05 15:33","pubTimestamp":1772695993,"startTime":"0","endTime":"0","summary":"Citigroup has issued a research report stating that RIBOLIFE-B (06938) is a leading enterprise in the siRNA field, possessing core advantages such as a differentiated drug pipeline and an advanced...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0648001328.SGD","LU2236285917.USD","LU0314106906.USD","LU0130517989.USD","LU1791807156.HKD","BK4588","IE00BSNM7G36.USD","LU0310800965.SGD","LU1668664300.SGD","LU2417539215.USD","BK4207","LU1244550221.USD","BK1161","BK4534","LU0072461881.USD","LU1244550494.USD","BK4559","C","LU0170899867.USD","LU1201861249.SGD","LU1506573853.SGD","LU2125154935.USD","LU2125154778.USD","LU1244550577.SGD","LU2456880835.USD","LU2462157665.USD","LU1366192091.USD","LU0130102774.USD","LU0128525689.USD","LU0980610538.SGD","LU0052756011.USD","LU2360032135.SGD","LU0477156953.USD","LU0320765646.SGD","LU0098860793.USD","LU0162691827.USD","BK4585","BK4566","LU1267930227.SGD","06938","BK4504","LU0106831901.USD","LU1162221912.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":-0.0516},{"period":"1month","weight":0.1353},{"period":"3month","weight":-0.2058},{"period":"6month","weight":0.0781},{"period":"ytd","weight":0.0781}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Suzhou Ribo Life Science Co Ltd is a China-based company primarily engaged in the oligonucleotide research and development, with a focus on small interfering ribonucleic acid (siRNA) therapeutics. The Company’s main business is engaged in the oligonucleotide drug innovation focused on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The Company’s drug pipelines include RBD4059, RBD5044, RBD7022, RBD7007, RBD2080, RBD1119, RBD1016 and others. The Company mainly conducts its business in the domestic market.","exchange":"SEHK","name":"RIBOLIFE-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RIBOLIFE-B(06938),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RIBOLIFE-B(06938) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RIBOLIFE-B,06938,RIBOLIFE-B股票,RIBOLIFE-B股票老虎,RIBOLIFE-B股票老虎国际,RIBOLIFE-B行情,RIBOLIFE-B股票行情,RIBOLIFE-B股价,RIBOLIFE-B股市,RIBOLIFE-B股票价格,RIBOLIFE-B股票交易,RIBOLIFE-B股票购买,RIBOLIFE-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RIBOLIFE-B(06938),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RIBOLIFE-B(06938) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}